Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Urology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.UROLOGY.2003.09.028PMID 14972481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)

  2006cited by this paper
• Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

  2004cited by this paper
• Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

  2004cited by this paper
• Different PSA assays lead to detection of prostate cancers with identical histological features.

  2002cited by this paper
• Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer.

  2002cited by this paper
• Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.

  2002cited by this paper
• PSA doubling time of prostate carcinoma managed with watchful observation alone.

  2001cited by this paper
• Prostate‐specific antigen: A surrogate endpoint for screening new agents against prostate cancer?

  2000cited by this paper
• Prostate specific antigen variation in patients without clinically evident prostate cancer.

  1999cited by this paper
• Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

  1999cited by this paper
• Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam)

  1999cited by this paper
• Evaluation of prostate‐specific antigen, digital rectal examination and transrectal ultrasonography in population‐based screening for prostate cancer: improving the efficiency of early detection

  1997cited by this paper
• Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

  1996cited by this paper
• Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population.

  1996cited by this paper
• European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies

  1995cited by this paper
• Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.

  1995cited by this paper
• Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.

  1994cited by this paper
• Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

  1993cited by this paper
• Screening for prostatic carcinoma with prostate specific antigen.

  1992cited by this paper
• Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.

  1992cited by this paper
• Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

  1992cited by this paper

• An AIE/PET-based fluorescent probe for Zn2+/Al3+ detection and its application in fluorescence-assisted diagnosis for prostate cancer

  2022cites this paper
• Prostate Specific Antigen Dynamics and Features in Prostate Cancer

  2021cites this paper
• PROSTATE-SPECIFIC ANTIGEN DYNAMICS IN DIAGNOSIS OF PROSTATE CANCER

  2019cites this paper
• Cancer/Testis Antigens Differentially Expressed in Prostate Cancer: Potential New Biomarkers and Targets for Immunotherapies

  2019cites this paper
• 8 Strategies for Repeat Prostate Biopsies

  2018cites this paper
• Serum relaxin-2 as a novel biomarker for prostate cancer

  2018cites this paper
• The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements

  2016cites this paper
• 64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies

  2016cites this paper
• ROLE OF ANTIBIOTIC THERAPY BEFORE PROSTATE BIOPSY IN PATIENTS WITH MARGINALLY ELEVATED PSA-A HOSPITAL BASED STUDY

  2016cites this paper
• Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial.

  2016cites this paper
• Antibiotics has incapability of reducing unnecessary prostate biopsies : a meta-analysis involving 2 , 035 patients

  2016cites this paper
• The absence of evidence is not the evidence of absence.

  2016cites this paper
• TREATMENT RESPONSE ON THE LEVEL OF PROSTATE SPECIFIC ANTIGEN (PSA)

  2015cites this paper
• Antibiotics may not decrease prostate-specific antigen levels or prevent unnecessary prostate biopsy in patients with moderately increased prostate-specific antigen levels: A meta-analysis.

  2015influential citation
• [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer].

  2015cites this paper
• Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome.

  2015cites this paper
• Biopsie der Prostata

  2014cites this paper
• The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml.

  2014cites this paper
• Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom

  2014cites this paper
• [Prostate biopsy. Update for indication, procedure, and future developments].

  2014cites this paper
• Screening for prostate cancer.

  2013cites this paper
• Wertigkeit der präoperativen Bildgebung beim Prostatakarzinom

  2013cites this paper
• The Effect of Antibiotherapy on Prostate-Specific Antigen Levels and Prostate Biopsy Results in Patients with Levels 2.5 to 10 ng/mL

  2013cites this paper
• Early detection, PSA screening, and management of overdiagnosis.

  2013cites this paper
• Screening for prostate cancer: an updated review

  2013cites this paper
• DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer.

  2013cites this paper
• Impacts of Antibiotic and Anti-Inflammatory Therapy on Serum Prostate Specific Antigen in Asymptomatic Men: Our Experience

  2012cites this paper
• PSA velocity does not aid the detection of prostate cancer in men with a prior negative biopsy: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden and Rotterdam, Netherlands

  2012cites this paper
• An examination of the dynamic changes in prostate‐specific antigen occurring in a population‐based cohort of men over time

  2012cites this paper
• Early Detection, Diagnosis, and Staging of Prostate Cancer

  2012cites this paper
• Advances in membrane proteomics and cancer biomarker discovery: Current status and future perspective

  2012cites this paper
• Individual and Mass Screening

  2012cites this paper
• Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.

  2011cites this paper
• Screening for prostate cancer.

  2011cites this paper
• SCREENING PROSTATE SPECIFIC ANTIGEN EFFECTS ON RACIAL DISPARATE MORTALITY: A PROPENSITY SCORE ANALYSIS

  2011cites this paper
• Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom

  2010cites this paper
• Dissecting the dynamics of serum prostate-specific antigen.

  2010cites this paper
• Parâmetros cinéticos do PSA em pacientes submetidos à biópsia de próstata

  2010cites this paper
• Changes in serum prostate-specific antigen after treatment with antibiotics in patients with lower urinary tract symptoms/benign prostatic hyperplasia with prostatitis.

  2010cites this paper
• Biopsie prostatique : techniques et indications

  2010cites this paper
• [Early detection of prostate cancer: is serum PSA testing alone sufficient?].

  2010cites this paper
• Improving Screening Strategies for Prostate Cancer

  2010cites this paper
• Früherkennung von Prostatakarzinomen Ist die Untersuchung des Serum-PSA alleine ausreichend?

  2010cites this paper
• On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.

  2010cites this paper
• Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

  2010cites this paper
• Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.

  2009cites this paper
• Infection/Inflammation Effectiveness of Antibiotics Given to Asymptomatic Men for an Increased Prostate Specific Antigen

  2009cites this paper
• Strategies for repeat prostate biopsies

  2009cites this paper
• Development of Novel Assays for Measuring Different Molecular Forms of Prostate Specific Antigen

  2009cites this paper
• Prostatic Diseases and Male Voiding Dysfunction Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability for Benign Prostatic Hyperplasia and Detection of Malignancy

  2009cites this paper
• Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen.

  2009cites this paper
• PSA – Quo vadis?

  2009cites this paper
• Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.

  2009cites this paper
• Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

  2009cites this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cites this paper
• Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

  2009cites this paper
• Bevolkingsonderzoek naar prostaatkanker

  2009cites this paper
• Prostate cancer screening: the continuing controversy.

  2008cites this paper
• Abnormal PSA tests--delays in referral.

  2008cites this paper
• Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

  2008cites this paper
• Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

  2008cites this paper
• The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer

  2008cites this paper
• Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.

  2008cites this paper
• Screening for Prostate Cancer: Digital rectal examination: outdated or still valuable?

  2008cites this paper
• Optimal measure of PSA kinetics to identify prostate cancer.

  2008cites this paper
• The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

  2008cites this paper
• The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis

  2008cites this paper
• [Clinical efficacy of prostatic biopsy. Experience in our center from 1990 to 2002].

  2008cites this paper
• Ambulatory and Office Urology ptimal Measure of PSA Kinetics to Identify rostate Cancer

  2008cites this paper
• Current applications for prostate-specific antigen doubling time.

  2008cites this paper
• American Family Physician

  2008cites this paper
• Eficacia clnica de la biopsia prosttica: Experiencia en nuestro centro 1990-2002

  2008cites this paper
• [Prognostic significance of "sawtooth" PSA and "stepwise" PSA].

  2007cites this paper
• Fluctuating prostate‐specific antigen levels in patients with initial negative biopsy: should we be reassured?

  2007cites this paper
• The Continuing Role of PSA in the Detection and Management of Prostate Cancer

  2007cites this paper
• Prostate biopsy: current status and limitations.

  2007cites this paper
• PSA "en dents de scie" et PSA "en escalier" : quelles implications pronostiques ?

  2007cites this paper
• Teile dieser Arbeit wurden in den folgenden Arbeiten publiziert

  2007cites this paper
• Methods of calculating prostate-specific antigen velocity.

  2007cites this paper
• Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

  2007cites this paper
• Screening of prostate cancer. Is it needed? Russian experience

  2006cites this paper
• Does PSA velocity predict prostate cancer in pre-screened populations?

  2006cites this paper
• The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  2006cites this paper
• PSA velocity and PSA slope

  2006cites this paper
• PSA velocity in conservatively managed BPH: Can it predict the need for BPH‐related invasive therapy?

  2006cites this paper
• Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.

  2006cites this paper
• PSA 2010 – Aufbruch in eine neue Ära der Früherkennung des Prostatakarzinom

  2006cites this paper
• Molecular markers of prostate cancer.

  2006cites this paper
• [PSA 2010--the beginning of a new era in early detection of prostate cancer].

  2006cites this paper
• PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.

  2006cites this paper
• Prostate-Specific Antigen ‘Velocity’ as a Diagnostic Test for Prostate Cancer

  2006cites this paper
• Carcinoma of the prostate: overview of the most common malignancy in men.

  2006cites this paper
• PSA and the Detection of Prostate Cancer After 2005. Part I

  2006cites this paper
• PSA and the Detection of Prostate Cancer After 2005. Part II: Ways Out of the PSA Dilemma?

  2006cites this paper
• Papel actual del antígeno prostático específico y otros marcadores en el diagnóstico del cáncer de próstata

  2006cites this paper
• Seminar article Molecular markers of prostate cancer

  2006cites this paper
• Population Based Screening for Prostate Cancer: prognostic findings of two subsequent screening rounds

  2006cites this paper
• [Utility of prostate specific antigen doubling time in repeat biopsy for prostate cancer].

  2006cites this paper
• Screening for prostate cancer.

  2006cites this paper
• Health Technology Assessment : l'antigène prostatique spécifique (PSA) dans le dépistage du cancer de la prostate

  2006cites this paper